Navigation Links
Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)
Date:10/8/2010

COVINGTON, Ky., Oct. 8 /PRNewswire/ -- Bexion Pharmaceuticals announced today that it has been awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI). The grant entitled "SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme" was awarded September 28, 2010 and covers a two year period.  This announcement from NCI follows their September 20, 2010 announcement selecting Bexion for a notable research collaboration with NCI's Nanotechnology Characterization Laboratory (NCL), part of a major program, the Alliance for Nanotechnology in Cancer, to advance the medical applications of nanotechnology.

Bexion's proprietary technology is based on Saposin C- dioleoylphosphatidylserine (dubbed "SapC-DOPS") and is a first-in-class nanovesicle therapeutic for the treatment of glioblastomas (GBM), pancreatic cancers, and other solid tumors.  These nanovesicles have preferential affinity for phosphatidylserine-enriched membrane patches which appear to be common in many types of tumor cells and tumor neovasculature.  Bexion's initial studies of SapC-DOPS nanovesicles have shown that they induce apoptosis in cancer cell lines and also demonstrated in vivo efficacy in multiple tumor models.

The intent of this Phase II SBIR grant is to identify and select optimized SapC-DOPS formulations and treatment methods for glioblastoma multiforme, suitable for advancing Bexion's drug toward planned human testing. Upon the completion of these studies, Bexion expects to have compelling evidence to progress into clinical development.

"This Phase II award will expedite our goal to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment," stated Dr. Ray Takigiku, Bexion's co-founder and CEO. "Of the 12,000 patients expected to be diagnosed with GBM this year, most will succumb within the first year. Clearly, there is an urgent demand for an efficacious anti-glioma drug."

This SBIR Phase II award is the fourth grant won by Bexion from the NCI. Past awards include Phase I grants for treating Metastatic Prostate, Pancreatic and Glioblastoma Multiforme.

About Bexion Pharmaceuticals:

Bexion Pharmaceuticals is focused on the development and commercialization of innovative cures for cancer.  Initial products are based on a proprietary platform technology licensed from Cincinnati Children's Hospital Medical Center.  The technology has demonstrated potential for development as therapeutics, diagnostic and surgical imaging reagents, and as carriers for other pharmaceutical agents, such as oligonucleotides.  For more information, visit www.bexionpharma.com.


'/>"/>
SOURCE Bexion Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Onyx Pharmaceuticals Provides Status Update on Carfilzomib
2. Onyx Pharmaceuticals Announces Teleconference to Provide Status Update on Carfilzomib
3. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
4. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
5. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
6. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
7. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
8. MAP Pharmaceuticals Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
9. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
10. Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
11. Transcept Pharmaceuticals to Present at BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):